Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences

NEW YORK, September 18, 2017 /PRNewswire/ --

If you want a Stock Review on MNK, HZNP, MYL, or NBIX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com have issued research reports on Mallinckrodt PLC (NYSE: MNK), Horizon Pharma PLC (NASDAQ: HZNP), Mylan N.V. (NASDAQ: MYL), and Neurocrine Biosciences Inc. (NASDAQ: NBIX). According to Visiongain's report titled - "Generic Drugs Market Forecast 2017-2027" - the generic drugs market is expected to grow at a CAGR of 8.8% in the first half of the forecast period and at a CAGR of 7.0% in the second half of the forecast period. The market is expected to grow at a CAGR of 7.9% from 2015 to 2027. The market is estimated at $384.0 billion in 2021 and $574.7 billion in 2027. Daily Stock Tracker published free research reports on these stocks today at:

http://dailystocktracker.com/register/

Mallinckrodt 

Staines-Upon-Thames, the UK headquartered Mallinckrodt PLC's stock saw a drop of 2.67%, finishing last Friday's trading session at $34.27. A total volume of 2.63 million shares was traded, which was above their three months average volume of 2.60 million shares. The Company's shares are trading below their 50-day moving average by 15.50%. Additionally, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, Middle-East, Africa, and internationally, have a Relative Strength Index (RSI) of 33.37.

On September 06^th, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'. See our free and comprehensive research report on MNK at:

http://dailystocktracker.com/registration/?symbol=MNK

Horizon Pharma 

Shares in Dublin, Ireland headquartered Horizon Pharma PLC ended at $12.11, down 1.46% from the last trading session. The stock recorded a trading volume of 7.89 million shares, which was above its three months average volume of 3.87 million shares. The Company's shares have advanced 1.85% in the past month and 17.69% over the previous three months. The stock is trading 5.67% below its 50-day moving average. Moreover, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the US and internationally, have an RSI of 38.11.

On September 11^th, 2017, Horizon Pharma named Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer, reporting directly to Timothy P. Walbert, Chairman, President, and CEO, effective immediately. Prior to the Company, Konstantinovsky was Vice President of global talent at Baxter International Inc., where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity, and talent acquisition. HZNP free research report is just a click away at:

http://dailystocktracker.com/registration/?symbol=HZNP

Mylan 

On Friday, shares in Hatfield, the UK-based Mylan N.V. recorded a trading volume of 20.12 million shares, which was above their three months average volume of 6.22 million shares. The stock declined 2.56%, closing the day at $32.03. The Company's shares have gained 5.12% in the last one month. The stock is trading 6.68% below its 50-day moving average. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 45.25.

On August 22^nd, 2017, research firm Argus downgraded the Company's stock rating from 'Buy' to 'Hold'.

On September 13^th, 2017, Mylan announced the appointment of Dennis Zeleny as Chief Human Relations Officer. He joins the Company with 30 years of experience leading global, corporate HR organizations and consulting on HR policy matters. Over the course of his career, Zeleny has demonstrated leadership in directing large-scale transformation and cultural changes, mergers and acquisitions, compensation and benefits design, corporate governance, talent management, and building global HR strategies that drive business results. Sign up for your complimentary report on MYL at:

http://dailystocktracker.com/registration/?symbol=MYL

Neurocrine Biosciences 

At the close of trading on Friday, shares in San Diego, California headquartered Neurocrine Biosciences Inc. recorded a trading volume of 1.31 million shares, which was above an their three months average volume of 895,080 shares. The stock finished the session 0.35% lower at $56.71. The Company's shares have gained 5.90% in the past month, 28.97% in the previous three months, and 46.54% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.50% and 21.16%, respectively. Furthermore, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US and internationally, have an RSI of 62.03. Register for free on DailyStockTracker.com and download the latest research report on NBIX at:

http://dailystocktracker.com/registration/?symbol=NBIX

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com